[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100295215":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":20,"locations":7,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":45,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":57,"locationsCount":7},{"fullName":5,"class":6},"AbbVie","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Venetoclax","Venetoclax will be administered orally.",[14,15],"ABT-199","GDC-0199",[17],{"name":18,"affiliation":5,"role":19},"ABBVIE INC.","STUDY_DIRECTOR",[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100295215","expanded-access-to-venetoclax-100295215",false,"NCT03123029","Expanded Access to Venetoclax","Exclusion Criteria:\n\n* There are other suitable treatment options.\n* The participant qualifies for ongoing clinical trials.","ALL","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[38,39,40,41,42,43,44],"Chronic Lymphocytic Leukemia (CLL)","Multiple Myeloma","Acute Myeloid Leukemia (AML)","Non-Hodgkin's Lymphoma","Acute Lymphoblastic Leukemia (ALL)","Amyloidosis","Plasma Cell Leukemia",[46,47,48,49,50,51],"Expanded Access","Pre-approval Access","Compassionate Use","Special Access Program","Named Patient Basis","Special Access Scheme","AVAILABLE","2026-01-29",{"date":55,"type":56},"2026-01-30","ACTUAL",{"name":5,"class":6}]